KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Research & Development (2016 - 2025)

Arbutus Biopharma's Research & Development history spans 13 years, with the latest figure at $5.8 million for Q3 2025.

  • For Q3 2025, Research & Development fell 59.52% year-over-year to $5.8 million; the TTM value through Sep 2025 reached $29.0 million, down 53.74%, while the annual FY2024 figure was $54.0 million, 26.68% down from the prior year.
  • Research & Development for Q3 2025 was $5.8 million at Arbutus Biopharma, up from $5.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $22.9 million in Q4 2022 and bottomed at $5.5 million in Q2 2025.
  • The 5-year median for Research & Development is $16.7 million (2021), against an average of $15.7 million.
  • The largest annual shift saw Research & Development soared 50.97% in 2021 before it tumbled 64.65% in 2025.
  • A 5-year view of Research & Development shows it stood at $19.2 million in 2021, then rose by 19.45% to $22.9 million in 2022, then fell by 23.47% to $17.6 million in 2023, then crashed by 49.84% to $8.8 million in 2024, then tumbled by 34.42% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Research & Development are $5.8 million (Q3 2025), $5.5 million (Q2 2025), and $9.0 million (Q1 2025).